Transaction · 0001231589-26-000005

MAHON PAUL A

MAHON PAUL A, EVP, GC, reported a transaction classified as grant at UNITED THERAPEUTICS Corp involving 49860.000000 shares for an estimated $0.00. Reported holdings after the transaction were 49860.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code AEVP, GC
UTHRUNITED THERAPEUTICS Corp
Filing timeFeb 26
Trade dateMar 15, 2023
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$503.60
Pre-filing
1mo ago1w ago1d ago
Returns since
7d -3.7%30d +3.8%90d +13.3%180d +2.9%1y +2.9%

UTHR price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
UTHR since 2026-02-26Filed 190 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
grant
Code A
Identifier
0001231589-26-000005
Stock Options
Transaction date
Mar 15, 2023
Filed Feb 26, 2026, 12:00 AM · 1079d delay
Shares
49.8k sh
$0 per share
Estimated value
$0
Computed from shares × price
Holdings after
49.8k sh
Direct

Filing warnings

Notes recorded with this filing
1 warning
delayed filingThe filing was reported 1079 calendar days after the transaction date.

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Delayed Filing Derivative Transaction Direct Ownership Large Holdings Increase
-16score
Filing-only score

-16

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

EVP & GENERAL COUNSEL

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    These performance-based stock options were initially awarded on March 15, 2023, subject to a three-year performance condition tied to average cash profit margin during 2023-2025, which was determined…

  2. F2

    These performance-based restricted stock units were initially awarded on March 15, 2023, subject to a three-year performance condition tied to average revenue growth during 2023-2025, which was determ…

  3. F3

    Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

  4. F4

    Not applicable as restricted stock units do not have an expiration date.

  5. F5

    These performance-based restricted stock units were initially awarded on March 15, 2023, subject to a three-year performance condition tied to clinical development performance during 2023-2025, which…

Original filing · 0001231589-26-000005
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

UTHR